My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

83.88 -0.02 (-0.02%)
Streaming Delayed Price Updated: 11:45 AM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 291,011
Open 83.83
Bid (Size) 83.83 (2)
Ask (Size) 83.92 (2)
Prev. Close 83.89
Today's Range 83.75 - 84.72
52wk Range 53.56 - 87.99
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire

Performance

YTD
+20.6%
+20.6%
1 Month
-2.4%
-2.4%
3 Month
+23.2%
+23.2%
6 Month
+38.5%
+38.5%
1 Year
+26.9%
+26.9%

More News

Read More
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
Via MarketMinute
Topics Intellectual Property
13 Analysts Have This To Say About Incyte
Via Benzinga
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market
Via Benzinga
Topics Stocks
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
From Incyte
Via Business Wire
Incyte Stock: A Deep Dive Into Analyst Perspectives (11 Ratings)
Via Benzinga
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children
Via Benzinga
Incyte Corp (NASDAQ:INCY) Emerges as a Top Value Investing Candidate
Via Chartmill
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
From Incyte
Via Business Wire
2 S&P 500 Stocks with Exciting Potential and 1 We Avoid
Via StockStory
Topics Stocks
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
3 Unpopular Stocks That Deserve a Second Chance
Via StockStory
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
From Incyte
Via Business Wire
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
From Incyte
Via Business Wire
Incyte (INCY) Stock Is Up, What You Need To Know
Via StockStory
Topics Economy
Tuesday's session: top gainers and losers in the S&P500 index
Via Chartmill
1 Profitable Stock to Keep an Eye On and 2 We Question
Via StockStory
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
Via MarketBeat
Incyte Corp (NASDAQ:INCY): A Prime Candidate for Value Investors Seeking Undervalued Stocks
Via Chartmill
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot
Via Benzinga
Topics Stocks
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
From Incyte
Via Business Wire
1 Mid-Cap Stock with Solid Fundamentals and 2 We Find Risky
Via StockStory

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 83.88
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 09/30/25 11:45 AM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 18.66B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.